TenX Keane Acquisition is a blank check company, also commonly referred to as a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. TenX is led by Xiaofeng Yuan, Chairman and Chief Executive Officer, and Taylor Zhang, Chief Financial Officer, who are growth-oriented executives with a long track record of value creation across industries.
![Citius Oncology logo](/files/LOGO/1851484-TENK.png)
Company profile
Ticker
CTOR, TENK
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
TenX Keane Acquisition
SEC CIK
CTOR stock data
Latest filings (excl ownership)
8-K/A
Completion of Acquisition or Disposition of Assets
26 Aug 24
8-K
Entry into a Material Definitive Agreement
16 Aug 24
25-NSE
Exchange delisting
13 Aug 24
10-Q
2024 Q2
Quarterly report
9 Aug 24
8-K
Departure of Directors or Certain Officers
2 Aug 24
425
Business combination disclosure
19 Jul 24
8-K
Entry into a Material Definitive Agreement
19 Jul 24
EFFECT
Notice of effectiveness
15 Jul 24
424B3
Prospectus supplement
12 Jul 24
Latest ownership filings
4/A
Leonard L Mazur
30 Aug 24
4/A
MYRON Z HOLUBIAK
30 Aug 24
4/A
Myron Czuczman
30 Aug 24
4/A
Jaime Bartushak
30 Aug 24
SC 13D
Citius Pharmaceuticals, Inc.
16 Aug 24
4
Eugene Myron Holuka
16 Aug 24
3
Eugene Myron Holuka
16 Aug 24
SC 13D/A
10XYZ Holdings LP
15 Aug 24
4
Suren G Dutia
14 Aug 24
4
MYRON Z HOLUBIAK
14 Aug 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
News
Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
6 Aug 24
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge
5 Aug 24
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval Of Merger With Citius Oncology; Citius Pharmaceuticals To Retain ~90% Majority Control Post Transaction
5 Aug 24
Press releases
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
9 Aug 24
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology
6 Aug 24
TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals
5 Aug 24
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
5 Aug 24
Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products
30 Jul 24